Agonist-selective effects of opioid receptor ligands on cytosolic calcium concentration in rat striatal neurons

Drug and Alcohol Dependence

Volumn 123, Issue 1-3, 2012, Pages 277-281

  Brailoiu, G Cristina ^a   Deliu, Elena ^a   Hooper, Robert ^a   Dun, Nae J ^a   Undieh, Ashiwel S ^b   Adler, Martin W ^a   Benamar, Khalid ^a   Brailoiu, Eugen ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Calcium imaging; Opioid receptors; Striatum

Indexed keywords

BETA ENDORPHIN; BUPRENORPHINE; CALCIUM; MORPHINE; OPIATE RECEPTOR;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CALCIUM CELL LEVEL; CELL SUBPOPULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BETA-ENDORPHIN; BUPRENORPHINE; CALCIUM; CORPUS STRIATUM; CYTOSOL; FLUORESCENT DYES; FURA-2; LIGANDS; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID;

RATTUS;

EID: 84861225016     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.11.021     Document Type: Article

References (36)

1. Amass L., Pukeleviciene V., Subata E., Almeida A.R., Pieri M.C., D'Egidio P., Stankova Z., Costa A., Smyth B.P., Sakoman S., Wei Y., Strang J. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. Addiction 2011, 104:142-151.
2. Barr E., Leslie S.W. Opioid peptides increase calcium uptake by synaptosomes from brain regions. Brain Res. 1985, 329:280-284.
3. Bolan E.A., Pan Y.X., Pasternak G.W. Functional analysis of MOR-1 splice variants of the mouse mu opioid receptor gene oprm. Synapse 2004, 51:11-18.
4. Brailoiu E., Hoard J.L., Filipeanu C.M., Brailoiu G.C., Dun S.L., Patel S., Dun N.J. Nicotinic acid adenine dinucleotide phosphate potentiates neurite outgrowth. J. Biol. Chem. 2005, 280:5646-5650.
5. Brailoiu G.C., Oprea T.I., Zhao P., Abood M.E., Brailoiu E. Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide. J. Biol. Chem. 2011, 286:29166-29174.
6. Cox B.M., Borsodi A., Caló G., Chavkin C., Christie M.J., Civelli O., Devi L.A., Evans C., Höllt V., Henderson G., Kieffer B., Kitchen I., Kreek M.J., Liu-Chen L.Y., Meunier J.C., Portoghese P.S., Shippenberg T.S., Simon E.J., Toll L., Traynor J.R., Ueda H., Wong Y.H. Opioid Receptors, Introductory Chapter 2009, IUPHAR Database. http://www.iuphar-db.org/DATABASE/FamilyIntroductionForward?familyId=50.
7. Deliu E., Tica A.A., Motoc D., Brailoiu G.C., Brailoiu E. Intracellular angiotensin II activates rat myometrium. Am. J. Physiol. Cell Physiol. 2011, 301:C559-C565.
8. Dhawan B.N., Cesselin F., Raghubir R., Reisine T., Bradley P.B., Portoghese P.S., Hamon M. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol. Rev. 1996, 48:567-592.
9. Di Sole F., Guerra L., Bagorda A., Reshkin S.J., Albrizio M., Minoia P., Casavola V. Naloxone inhibits A6 cell Na(+)/H(+) exchange by activating protein kinase C via the mobilization of intracellular calcium. Exp. Nephrol. 2001, 9:341-348.
10. Ding Y.Q., Kaneko T., Nomura S., Mizuno N. Immunohistochemical localization of mu-opioid receptors in the central nervous system of the rat. J. Comp. Neurol. 1996, 367:375-402.
11. Ding Z., Raffa R.B. Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br. J. Pharmacol. 2009, 157:831-843.
12. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 1985, 260:3440-3450.
13. Haller H., Lindschau C., Erdmann B., Quass P., Luft F.C. Effects of intracellular angiotensin II in vascular smooth muscle cells. Circ. Res. 1996, 79:765-772.
14. Ide S., Minami M., Satoh M., Uhl G.R., Sora I., Ikeda K. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology 2004, 29:1656-1663.
15. Kahan M., Srivastava A., Ordean A., Cirone S. Buprenorphine: new treatment of opioid addiction in primary care. Can. Fam. Physician 2011, 57:281-289.
16. Kenakin T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol. Sci. 1995, 16:232-238.
17. Lee J.W., Joshi S., Chan J.S., Wong Y.H. Differential coupling of mu-, delta-, and kappa-opioid receptors to G alpha16-mediated stimulation of phospholipase C. J. Neurochem. 1998, 70:2203-2211.
18. Lutfy K., Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr. Neuropharmacol. 2004, 2:395-402.
19. Mansour A., Khachaturian H., Lewis M.E., Akil H., Watson S.J. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J. Neurosci. 1987, 7:2445-2464.
20. Negus S.S., Bidlack J.M., Mello N.K., Furness M.S., Rice K.C., Brandt M.R. Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav. Pharmacol. 2002, 13:557-570.
21. Pergolizzi J., Boger R.H., Budd K., Dahan A., Erdine S., Hans G., Kress H.G., Langford R., Likar R., Raffa R.B., Sacerdote P. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008, 8:287-313.
22. Raynor K., Kong H., Chen Y., Yasuda K., Yu L., Bell G.I., Reisine T. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol. Pharmacol. 1994, 45:330-334.
23. Re R.N., Cook J.L. Mechanisms of disease: intracrine physiology in the cardiovascular system. Nat. Clin. Pract. Cardiovasc. Med. 2007, 4:549-557.
24. Reig F., Busquets M.A., Haro I., Rabanal F., Alsina M.A. Interaction of opiate molecules with lipid monolayers and liposomes. J. Pharm. Sci. 1992, 81:546-550.
25. Reig F., Espigol C., Garcia Anton J.M., Valencia G., Alsina M.A. A physicochemical study of the interaction of phosphatidylinositol with buprenorphine and naloxone. J. Bioenerg. Biomembr. 1988, 20:533-549.
26. Sanchez-Blazquez P., Gomez-Serranillos P., Garzon J. Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. Brain Res. Bull. 2001, 54:229-235.
27. Schoniger S., Wehming S., Gonzalez C., Schobitz K., Rodriguez E., Oksche A., Yulis C.R., Nurnberger F. The dispersed cell culture as model for functional studies of the subcommissural organ: preparation and characterization of the culture system. J. Neurosci. Methods 2001, 107:47-61.
28. Standifer K.M., Pasternak G.W. G proteins and opioid receptor-mediated signalling. Cell. Signal. 1997, 9:237-248.
29. Toll L., Berzetei-Gurske I.P., Polgar W.E., Brandt S.R., Adapa I.D., Rodriguez L., Schwartz R.W., Haggart D., O'Brien A., White A., Kennedy J.M., Craymer K., Farrington L., Auh J.S. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res. Monogr. 1998, 178:440-466.
30. Trescot A.M., Helm S., Hansen H., Benyamin R., Glaser S.E., Adlaka R., Patel S., Manchikanti L. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008, 11:S5-S62.
31. Ueda H., Miyamae T., Fukushima N., Takeshima H., Fukuda K., Sasaki Y., Misu Y. Opioid mu- and kappa-receptor mediate phospholipase C activation through Gi1 in Xenopus oocytes. Brain Res. Mol. Brain Res. 1995, 32:166-170.
32. Undieh A.S. Pharmacology of signaling induced by dopamine D(1)-like receptor activation. Pharmacol. Ther. 2010, 128:37-60.
33. Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B., Weinstein H., Javitch J.A., Roth B.L., Christopoulos A., Sexton P.M., Miller K.J., Spedding M., Mailman R.B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 2007, 320:1-13.
34. Walsh S.L., Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003, 70:S13-S27.
35. Xu J., Xu M., Rossi G.C., Pasternak G.W., Pan Y.X. Identification and characterization of seven new exon 11-associated splice variants of the rat mu opioid receptor gene, OPRM1. Mol. Pain 2011, 7:9.
36. Zhu J., Luo L.Y., Li J.G., Chen C., Liu-Chen L.Y. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. J. Pharmacol. Exp. Ther. 1997, 282:676-684.